| 35th week of 2011 patent applcation highlights part 37 |
| Patent application number | Title | Published |
|---|
| 20110212863 | LUBRICATING OIL COMPOSITION IN CONTACT WITH SILVER-CONTAINING MATERIAL - The present invention provides a lubricating oil composition in contact with a silver-containing material, which comprises: a lubricant base oil made of a mineral base oil and/or a synthetic base oil; (A) metallic detergent; (B) one or more species of alkenyl succinimide and/or boron-containing alkenyl succinimide; and (C) zinc dialkyl dithiophosphate, wherein the content of these components to the total mass of the lubricating oil composition are defined as, (A) component: 0.12-2.0 mass % as metal content; (B) component: 0-0.03 mass % as boron content, 0.005 mass % to less than 0.08 mass % as nitrogen content, and the mass ratio (B/N) between the boron content (B) and the nitrogen content (N) is 0-0.55; and (C) component: 0.005-0.10 mass % as phosphorous content. As a lubricating oil in contact with silver-containing material, the lubricating oil composition can inhibit sulfidation corrosion of silver while containing zinc dialkyl dithiophosphate. | 2011-09-01 |
| 20110212864 | BENZOTRIAZOLE COMPOSITIONS - The invention relates to novel (benzo)triazole compositions comprising mixtures of benzotriazoles and N-substituted benzotriazoles in functional liquids, e.g. mineral oil. The mixtures can be prepared from readily obtainable starting materials, such as tolutriazole (TTA), alkyl aldehydes and cycloalkanols. The invention furthermore relates to a process for protecting metals, which are in contact with functional liquids comprising the mixtures. | 2011-09-01 |
| 20110212865 | Gluconic acid containing photoresist cleaning composition for multi-metal device processing - A microelectronic photoresist cleaning composition suitable for cleaning multi-metal microelectronic devices and to do so without any substantial or significant galvanic corrosion occurring when there is a subsequent rinsing step employing water. | 2011-09-01 |
| 20110212866 | WATER-RICH STRIPPING AND CLEANING FORMULATION AND METHOD FOR USING SAME - The present invention relates to water-rich formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, residues from Al back-end-of-the-line interconnect structures, as well as contaminations. The formulation comprises: hydroxylamine; corrosion inhibitor containing a mixture of alkyl dihydroxybenzene and hydroxyquinoline; an alkanolamine, a water-soluble solvent or the combination of the two; and at least 50% by weight of water. | 2011-09-01 |
| 20110212867 | DIMETHYLSULFOXIDE FORMULATION IN MIXTURE WITH ADDITIVE FOR LOWERING THE CRYSTALLIZATION POINT OF SAME, AND APPLICATIONS OF SAID MIXTURE - Use of at least one diol and/or of at least one triol as a dimethyl sulfoxide (DMSO) additive for lowering the crystallization point thereof. The DMSO formulation is used in combination with the abovementioned additive as a paint-stripping composition, a surface-cleaning composition, a graffiti-cleaning composition, a surface-cleaning composition in the microelectronics field, such as a photoresist stripper, a DMSO-based agrochemical composition, or as a constituent of an abovementioned composition, as a polymer-dissolving solvent, or as a constituent of a composition that is useful in the field of cosmetology or pharmacy. | 2011-09-01 |
| 20110212868 | Solid Laundry Detergent Composition Having an Excellent Anti-Encrustation Profile - A solid laundry detergent composition including: (a) greater than 5 wt % detersive surfactant; (b) greater than 5 wt % carbonate salt (c) from 0.05 wt % to 10 wt % calcium carbonate crystal growth inhibitor selected from the group consisting of 1-hydroxyethanediphosphonic acid and salt thereof; N,N-dicarboxymethyl-2-aminopentane-1,5-dioic acid and salt thereof; 2-phosphonobutane-1,2,4-tricarboxylic acid and salt thereof; and any combination thereof; (d) from 0.05 wt % to 10 wt % carboxylate polymer having a molecular weight of from 3,000 Da to 10,000 Da; (e) from 0 wt % to 10 wt % zeolite builder; (f) from 0 wt % to 10 wt % phosphate builder; (g) optionally from 0 wt % to 10 wt % silicate salt; (h) optionally from 0 wt % to 10 wt % layered silicate; and (i) other detergent ingredients. | 2011-09-01 |
| 20110212869 | Solid Laundry Detergent Composition Comprising C.I. Fluorescent Brightener 260 in Alpha-Crystalline Form - A solid laundry detergent composition including: (a) detersive surfactant; (b) C.I. fluorescent brightener 260 in alpha-crystalline form; (c) from 0 wt % to 10 wt % zeolite builder; (d) from 0 wt % to 10 wt % phosphate builder; (e) optionally from 0 wt % to 10 wt % silicate salt; (f) optionally from 0 wt % to 10 wt % layered silicate; and (g) other detergent ingredients. | 2011-09-01 |
| 20110212870 | Solid Laundry Detergent Composition Comprising Guerbet Alcohol-Based Detersive Surfactant - A solid laundry detergent composition including: (a) secondary alcohol-based detersive surfactant; (b) from 0 wt % to 10 wt % zeolite builder; (c) from 0 wt % to 10 wt % phosphate builder; (d) optionally from 0 wt % to 10 wt % silicate salt; (e) optionally from 0 wt % to 10 wt % layered silicate; and (f) other detergent ingredients. | 2011-09-01 |
| 20110212871 | Composition - A multi-phase surface cleaning composition. A first phase comprises an acidic cleaning formulation. A second phase comprises an alkaline cleaning formulation. The second phase includes a synthetic clay component. | 2011-09-01 |
| 20110212872 | Composition Comprising Polyethylene Glycol Polymer and Amylase - A solid particulate laundry detergent composition including: (a) polyethylene glycol polymer including a polyethylene glycol backbone and polyvinyl acetate side chains, wherein the average molecular weight of the polyethylene glycol backbone is in the range of from 4,000 Da to 8,000 Da, wherein the molecular weight ratio of the polyethylene glycol backbone to the polyvinyl acetate side chains is in the range of from 1:1.2 to 1:2, and wherein the average number of graft sites per ethylene oxide units is in the range of from 0.2 to 0.4; (b) amylase with greater than 90% identity to the AA560 alpha amylase endogenous to | 2011-09-01 |
| 20110212873 | Composition Comprising Substituted Cellulosic Polymer and Amylase - A solid particulate laundry detergent composition including: (a) substituted cellulosic polymer including carboxymethyl substituent groups, and having a degree of substitution (DS) of at least 0.55, and having a degree of blockiness (DB) of at least 0.35, and having a DS+DB is in the range of from 1.05 to 2.00; (b) amylase with greater than 90% identity to the AA560 alpha amylase endogenous to | 2011-09-01 |
| 20110212874 | Composition Comprising Co-Bleach Particle and Amylase - A solid particulate laundry detergent composition including: (a) co-bleach particle including bleach activator, source of hydrogen peroxide and optionally bleach catalyst; (b) amylase with greater than 90% identity to the AA560 alpha amylase endogenous to | 2011-09-01 |
| 20110212875 | Solid Laundry Detergent Composition Comprising Brightener in Micronized Particulate Form - A solid laundry detergent composition including: | 2011-09-01 |
| 20110212876 | CLEANING COMPOSITION COMPRISING AMYLASE VARIANTS WITH HIGH STABILITY IN THE PRESENCE OF A CHELATING AGENT - The present invention relates to cleaning compositions comprising variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme and cleaning processes comprising such compositions. | 2011-09-01 |
| 20110212877 | DETERGENT COMPOSITION - Peptide aldehydes containing a ureido group are effective as stabilizers for protease in a detergent composition, and as stabilizers for a second enzyme in a liquid composition with a protease. | 2011-09-01 |
| 20110212878 | PRODUCT AND METHOD OF TREATMENT - A method and related packaged product for forming a surface treatment liquid involves contacting two solids to form a liquid, particularly an ionic liquid under ambient conditions at the locus of use. | 2011-09-01 |
| 20110212879 | CONCENTRATED SHAMPOO - Concentrated shampoo composition comprising from 25 to 38% wt. C10-C14 ether sulphate as cleansing surfactant, from 0.5 to 5% salt and wherein the zero shear viscosity of the composition is from 2 to 2000 Pa·s and the composition comprises 90% vol. or more composition in the nematic discotic phase. | 2011-09-01 |
| 20110212880 | SURFACTANT COMPOSITION - Provided is a surfactant composition having excellent fluidity after long-term storage at a low temperature (5° C.) and excellent foamability when diluted. | 2011-09-01 |
| 20110212881 | ALEURONE AS A PREBIOTIC FIBER FOR IMPROVED INTESTINAL HEALTH - The present invention is directed to methods of treating, maintaining or improving the feces quality and gastrointestinal tract health of mammals. The present invention is further directed to food products that can be used to treat, maintain or improve the feces quality and gastrointestinal tract health of mammals. In at least one aspect of the invention, the method includes introducing aleurone into the diet of a mammal. In another aspect the food product includes aleurone. | 2011-09-01 |
| 20110212883 | RADICAL SCAVENGER AND ACTIVE OXYGEN ELIMINATING AGENT - It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-β-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient. | 2011-09-01 |
| 20110212884 | GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS - A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps. | 2011-09-01 |
| 20110212885 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING PEPTIDES AS PRESERVATIVE - A method and a contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight. | 2011-09-01 |
| 20110212886 | PHARMACEUTICAL COMPOSITIONS COMPRISING CASEIN DERIVED PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles. | 2011-09-01 |
| 20110212887 | METHODS OF TREATING OBESITY USING ENTEROSTATIN - The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin deficiency include overweight, obesity, metabolic disorders, hypertension, lipid related disorders, and type II diabetes. | 2011-09-01 |
| 20110212888 | Diet and methods for improving learning capacity, mood and behavior in mammals - This invention provides a method of improving mood and learning capacity in a mammal by giving the mammal a meal of low protein food, followed by a second meal of high glycemic index carbohydrate. A composition to be given to a mammal to improve mood and learning capacity and to reduce aggressive behavior contains at least one tyrosine uptake competitive amino acid in a ratio of 0.5% to 2% to protein. The tyrosine competitive amino acid preferred is leucine, isoleucine or valine. | 2011-09-01 |
| 20110212889 | USE OF LEPTIN FOR THE TREATMENT OF FATTY LIVER DISEASES AND CONDITIONS - The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis. | 2011-09-01 |
| 20110212890 | METASTIN DERIVATIVE AND USE THEREOF - Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in the blood and can have an excellent cancer metastasis inhibiting activity, an excellent cancer proliferation inhibiting activity, an excellent gonadotropin secretion inhibiting activity, an excellent sex hormone secretion inhibiting activity and the like by binding the metastin derivative to polyethylene glycol. | 2011-09-01 |
| 20110212891 | AZEPINONE DERIVATIVES - The present invention relates to a compound represented by formula (I): wherein R | 2011-09-01 |
| 20110212892 | AGENT FOR TREATMENT OF DIABETES - The present invention provides a hypoglycemic agent useful for treating diabetes or other similar diseases which has no adverse effects. Furthermore, the present invention provides a hypoglycemic agent comprising a combination of an antidiabetic drug and 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propanoic acid or a pharmaceutically acceptable salt thereof. | 2011-09-01 |
| 20110212893 | NELL-1 ENHANCED BONE MINERALIZATION - Provided herein are methods for enhancing bone mineralization for bone repair or regeneration and compositions and grafts therefor. Methods for screening agents that enhance or modulate NELL-1 gene expression or NELL-1 protein production in a cell are also provided. | 2011-09-01 |
| 20110212894 | DECELLULARIZATION METHOD FOR SCAFFOLDLESS TISSUE ENGINEERED ARTICULAR CARTILAGE OR NATIVE CARTILAGE TISSUE - Methods for fabricating a tissue-engineered construct comprising: providing a tissue-engineered construct, wherein the tissue-engineered construct is derived from a xenogenic source; and decellularizing the tissue-engineered construct. | 2011-09-01 |
| 20110212895 | Treatment of Cognitive and Learning Impairment - Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders. | 2011-09-01 |
| 20110212896 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 2011-09-01 |
| 20110212897 | WNT3A FOR INHIBITION OF SCARRING - Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin. | 2011-09-01 |
| 20110212898 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 2011-09-01 |
| 20110212899 | Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative - It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal sensitivity and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal sensitivity accompanying therewith. | 2011-09-01 |
| 20110212900 | METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PAIN ASSOCIATED WITH HEMATOPOIETIC CELL TRANSPLANTATION - A method for prophylactic and/or therapeutic treatment of a pain associated with hematopoietic cell transplantation, which comprises the step of administrating thrombomodulin to a mammal. | 2011-09-01 |
| 20110212901 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): | 2011-09-01 |
| 20110212902 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 2011-09-01 |
| 20110212903 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 2011-09-01 |
| 20110212904 | GALACTOSYLATED PRO-DRUGS OF NON-STEROIDAL ANTI-INFLAMMATORIES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS AND REDUCED TOXICITY OF THE STARTING DRUG - Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide. | 2011-09-01 |
| 20110212905 | CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]- BENZENE HEMIHYDRATE - A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum. | 2011-09-01 |
| 20110212906 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula: | 2011-09-01 |
| 20110212907 | HEXADECASACCHARIDES WITH ANTITHROMBOTIC ACTIVITY, INCLUDING A COVALENT BOND AND AN AMINO CHAIN - The present invention relates to novel synthetic hexadecasaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof. | 2011-09-01 |
| 20110212908 | TOPICAL COMPOSITIONS AND THE USE THEREOF - The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms on the skin of warm-blooded animals with coats. | 2011-09-01 |
| 20110212909 | Use of Ginsenoside Compound K in the Preparation of a Medicament for the Prevention and Treatment of Atherosclerosis - The invention relates to the fields of Chinese drugs and chemical drugs, specifically, drugs comprising ginsenoside compounds, methods of using ginsenoside compound K shown in Formula 1 for prevention and treatment of atherosclerosis and uses of ginsenoside compound K in the preparation of a medicament for prevention and treatment of atherosclerosis. | 2011-09-01 |
| 20110212910 | ANTIOXIDANT - To provide an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and is used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol as an active ingredient. | 2011-09-01 |
| 20110212911 | TRANSCRIPTION FACTOR INHIBITORS AND RELATED COMPOSITIONS, FORMULATIONS AND METHODS - The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular. | 2011-09-01 |
| 20110212912 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 2011-09-01 |
| 20110212913 | THERAPEUTIC COMPOSITIONS COMPRISING PHENOLIC ACIDS FOR TREATING CONDITIONS RELATED TO INAPPROPRIATE PLATELET AGGREGATION - The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C | 2011-09-01 |
| 20110212914 | STABILIZED PENTOSAN POLYSULFATE (PPS) FORMULATIONS AND METHODS OF ANALYZING THEM - Various pentosan polysulfate (PPS) formulations useful for treatment of osteoarthritis, interstitial cystitis, and other conditions of mammals are provided. These formulations showed improved resistance to degradation and discoloration and improved stability at physiological pH, even after sterilization. Capillary electrophoresis analysis of these formulations indicates that various formulations remain stable under conditions that caused degradation of PPS in prior art PPS formulations. | 2011-09-01 |
| 20110212915 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. | 2011-09-01 |
| 20110212916 | Method and means for improving bowel health - A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and/or the grain comprises a reduced level of SBEIIa enzyme activity and/or protein relative to wild-type grain. | 2011-09-01 |
| 20110212917 | AGENT FOR AMELIORATING BRAIN HYPOFUNCTION - Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto. | 2011-09-01 |
| 20110212918 | BORON-CONTAINING SMALL MOLECULES - This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections. | 2011-09-01 |
| 20110212919 | PROTEIN CROSS-LINKING INHIBITOR - The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas ( | 2011-09-01 |
| 20110212920 | N-Substituted Benzene Sulfonamides - Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. | 2011-09-01 |
| 20110212921 | SYNTHESIS AND FORMULATIONS OF SALTS OF ISOPHOSPHORAMIDE MUSTARD AND ANALOGS THEREOF - Disclosed herein are formulations and methods of manufacture of compounds of formula (E): | 2011-09-01 |
| 20110212922 | PROCESSES FOR THE PREPARATION OF PHOSPHATIDE SALTS - The present invention discloses processes a process for the preparation of phosphatide-salt complexes, the process including the steps of: using at least one raw material lecithin as a substrate; and enzymatically processing at least one raw material lecithin with phospholipase-D, racemic or enantiomerically-pure serine, and/or amine in an aqueous carboxylate-salt-complex solution, wherein the step of processing is performed in a single-phase reaction environment, to produce phosphatide-salt complexes having a structural fatty-acid chain derived from at least one raw material lecithin. Preferably, the step of processing is performed at a pH in the range of about 4.5-8.0 at a temperature in the range of about 25-60° C. Preferably, the aqueous carboxylate-salt-complex solution is formed from an aqueous solution of a carboxylic acid with a chain length of C2-C8 and a salt in an approximately 1:2 (weight per weight) acid-to-salt ratio. | 2011-09-01 |
| 20110212923 | Phosphate Derivatives of Substituted Benzoxazoles - The present invention relates to phosphate derivatives of estrogen receptor beta agonists, compositions thereof, preparations thereof, and uses thereof. Formula (I). | 2011-09-01 |
| 20110212924 | COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES - Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded. | 2011-09-01 |
| 20110212925 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2011-09-01 |
| 20110212926 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS - The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided. | 2011-09-01 |
| 20110212927 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME - The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages. | 2011-09-01 |
| 20110212928 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment. | 2011-09-01 |
| 20110212929 | Protein Kinase Inhibitors - Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: | 2011-09-01 |
| 20110212930 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 2011-09-01 |
| 20110212931 | ANTIOXIDANT - Provided is an antioxidant which is highly safe, inhibits oxidation of a biological component, in particular, a lipid, and may be used as a drug, food or drink, a food additive, an external preparation for skin, or the like. The antioxidant contains a compound selected from a cyclolanostane compound and a lophenol compound as an active ingredient. | 2011-09-01 |
| 20110212932 | AQUEOUS CLEAR SOLUTIONS OF FLUOCINOLONE ACETONIDE FOR TREATMENT OF OTIC INFLAMMATION - A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers. | 2011-09-01 |
| 20110212933 | Antiseptic Compositions for the Treatment of Infections - The invention provides antiseptic compositions that comprise a wide spectrum antiseptic component (WSAC) and optionally one or more other active ingredients. The WSAC comprises an alcohol, one or more antimicrobial phenol compounds, one or more antimicrobial agents, a solvent and optionally, one or more non-ionic detergents. Additional components such as additional active agents, and thickeners can also be optionally added. The antiseptic compositions have a wide-spectrum of antiseptic activity against microorganisms and exhibit minimal toxicity and minimal irritation and can be used to treat and/or prevent dermal, mucosal, cuticle (such as nail or hoof) or genital infections in a patient. | 2011-09-01 |
| 20110212934 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST - Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam. | 2011-09-01 |
| 20110212935 | COMPOSITIONS AND TREATMENT METHODS-4 - The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane. | 2011-09-01 |
| 20110212936 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF - The present invention provides novel high-valent palladium fluoride complexes. The complexes typically include multi-dentate ligands that stabilize the octahedral coordination sphere of the palladium(IV) atom. These complexes are useful in fluorinating organic compounds, in particular aryl-containing compounds. The invention is particularly useful for fluorinating compounds with | 2011-09-01 |
| 20110212937 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION - The present disclosure provides a series of compounds of the formula (I) | 2011-09-01 |
| 20110212938 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 - The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient. | 2011-09-01 |
| 20110212939 | Heterocyclic GPCR Agonists - Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity. | 2011-09-01 |
| 20110212940 | S1P Receptor Modulating Compounds and Use Thereof - The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions. | 2011-09-01 |
| 20110212941 | Imidazoisoindole Neuropeptide S Receptor Antagonists - The present invention is directed to imidazoisoindole compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved. | 2011-09-01 |
| 20110212942 | INHIBITORS OF POLO-LIKE KINASE - The present invention provides compounds having a structure according to Formula (I): | 2011-09-01 |
| 20110212943 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS - Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, neurode-generative disorders etc. | 2011-09-01 |
| 20110212944 | 2-OXO-1-PYRROLIDINE DERIVATIVES - This invention relates to novel 2-oxo-1-pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as a synaptic vesicle protein 2A (SV2A) ligand and/or a sodium channel blocker. | 2011-09-01 |
| 20110212945 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH). | 2011-09-01 |
| 20110212946 | Quinolone Neuropeptide S Receptor Antagonists - The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved. | 2011-09-01 |
| 20110212947 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia. | 2011-09-01 |
| 20110212948 | TREATMENT OF NEONATE FOALS WITH MELOXICAM - A method of administering meloxicam containing compositions to neonate foals of 6 weeks of age or less is provided. The inventors have discovered that foals of 6 weeks of age or less can have meloxicam administered at a dosage of 0.6 mg/kg without any negative or adverse reaction by the foal. The method also provides a dosing regimen for obtaining first peak plasma concentrations of approximately 800 ng/ml, average plasma concentration levels of 200 ng/ml for 6 hours after a single dose, and sustained plasma concentration levels of 100 ng/ml with twice daily dosing. | 2011-09-01 |
| 20110212949 | Heterocyclic Compounds as Pesticides - The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation. | 2011-09-01 |
| 20110212950 | 4,4-DISUBSTITUTED PIPERIDINES - The application relates to 4,4-disubstituted piperidines of the general formula (I) and their salts, preferably their pharmaceutically acceptable salts, in which R | 2011-09-01 |
| 20110212951 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2011-09-01 |
| 20110212952 | 3,4-DIHYDROBENZOXAZINE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VRI) ACTIVITY - A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR | 2011-09-01 |
| 20110212953 | Polymorph Form II of Tanaproget - Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject. | 2011-09-01 |
| 20110212954 | ALPHA-LIPOIC ACID DERIVATIVES AND THEIR USE IN DRUG PREPARATION - The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is —NH—R | 2011-09-01 |
| 20110212955 | ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER - The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R | 2011-09-01 |
| 20110212956 | Pyrazolopyrimidines for treating CNS disorders - Substituted pyrazolopyrimidine derivatives of formula (I) | 2011-09-01 |
| 20110212957 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 2011-09-01 |
| 20110212958 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES - The invention relates to fatty acid raloxifene derivatives; compositions comprising an effective amount of a fatty acid raloxifene derivative; and methods for treating osteoporosis or preventing invasive breast cancer in postmenopausal women comprising the administration of an effective amount of a fatty acid raloxifene derivative. | 2011-09-01 |
| 20110212959 | Cyanoisoquinoline Compounds and Methods of Use Thereof - The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure: | 2011-09-01 |
| 20110212960 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER - The invention relates to novel pyrazolopyrimidinones according to formula (I). | 2011-09-01 |
| 20110212961 | Pyrazole Derivatives as Kinase Inhibitors - The present invention provides compounds having the general structure I, or a pharmaceutically acceptable salt thereof: | 2011-09-01 |
| 20110212962 | P38 MAP KINASE INHIBITORS - There are provided inter alia compounds of formula (I) wherein R | 2011-09-01 |
| 20110212963 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, —COORc-CO—Rc or —CO—NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors. | 2011-09-01 |
